公开(公告)号：US20240116920A1

公开(公告)日：2024-04-11

申请号：US18254927

申请日：2021-11-29

Applicant: KOREA PHARMA CO., LTD. ,  EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

Inventor： Soo Sung KANG ,  Eun Sun PARK ,  Eun Hee PARK ,  Sun Joo LEE ,  Seung Hee HAN

IPC: C07D471/04 ,  A61P1/16

CPC classification number: C07D471/04 ,  A61P1/16

Abstract: Provided is a novel JAK-specific inhibitor compound and a method for preparing the same. The compound of the provided can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases. In particular, due to its high selectivity for JAK1, the compound of the provided can exhibit better therapeutic effects on inflammatory diseases and autoimmune diseases at a low dose and with fewer side effects and can be expected to be effective in preventing and treating liver fibrosis.

公开(公告)号：US20220220109A1

公开(公告)日：2022-07-14

申请号：US17613291

申请日：2020-05-27

Applicant: KOREA PHARMA CO., LTD.

Inventor： Soosung KANG ,  Eun Sun PARK ,  Eun Hee PARK ,  Seung Hee HAN

IPC: C07D471/04

Abstract: The present invention relates to a JAK inhibitor compound and a pharmaceutical composition including the same. More specifically, the present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutical composition including the same. The structure of the compound of Formula I is described in the specification. The compound of the present invention can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases.